(KITE) (KITE) Stock Price, News & Analysis

Company Overview

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Key Stats

• Today's Range: $179.79 to $179.79
• 50-Day Range: N/A
• 52-Week Range: $39.82 to $179.99
• Volume: N/A
• Average Volume: 1.65 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KITE Stock Analysis - Frequently Asked Questions

How were (KITE)'s earnings last quarter?

(KITE) (NASDAQ:KITE) announced its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.75) by $0.05. The firm's revenue was up .0% compared to the same quarter last year.

What other stocks do shareholders of (KITE) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (KITE) investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX) and United Airlines (UAL).

Company Calendar

• Last Earnings: 2/28/2017
• Today: 8/05/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KITE
• CIK: 1510580
• Web: www.kitepharma.com
• Phone: +1-310-8249999
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A